Role of personalized microRNA-124 Expression in Ovarian Cancer

Document Type : Original Article


1 Clinical Fellowship, Department of Orthopedic and Traumatology, Universitätsklinikum Bonn, Bonn, Germany

2 Department of Orthopedic and Traumatology, Universitätsklinikum Bonn, Bonn, Germany

3 Department of Genetics, Faculty of Life Science, Azad University of Tehran Medical Sciences Branch, Tehran, Iran

4 Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran

5 Department of Radiology, Zahedan University of Medical Science, Zahedan, Iran



Introduction: MicroRNA-124 (miR-124) is moderated in some human malignancies and is associated with tumor advancement. But, its expression and clinical importance in ovarian carcinoma is still unclear. Thus, the goal of this study was to feature the clinical importance of personalized miR-124 expression in ovarian carcinoma. Methods: 94 women ovarian cancer tissues and 26 normal ovarian tissues were accumulated from patients. We used Real-time PCR to quantify the expression of personalized miR-124 in clinical ovarian carcinoma specimen and normal tissues. Moreover, we measured the miR-124 relationship with clinicopathologic characteristics and the ovarian carcinoma survival. Results: The lesser expression of miR-124 in tumor tissues can be found in compared with normal tissue using PCR method (P < 0.05). Our data exhibited that there is a notable association among low expression of miR-12 and clinical staging of ovarian carcinoma (P = 0.023). Nevertheless, miR-124 expression was not notably associated with age (P = 0. 671), differentiation status (P = 0.512), lymph node metastasis (P = 0.415) and histological subtypes (0.547). Kaplan-Meier survival analysis and log-rank test were applied in present study. These tests showed the less expression on patients had markedly short-term survival time in comparison with high expression group (P = 0.022). Multivariate Cox proportional hazards model analysis revealed that less expression of miR-124 and clinical staging were contribute to short-term survival in patients with ovarian carcinoma. The HR of the low miR-124 expression group was calculated to be 2.532 (95% CI: 1.572-9.237, P = 0.021), (clinical staging HR: 2.532; 95% CI: 1.321-9.241, P = 0.032).
Conclusions: These findings suggested that personalized miR-124 could be considered as an independent prognostic factor for ovarian carcinoma patients. Our findings suggested that low expression of personalized miR-124 has prognostic worthiness in ovarian.